Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …

Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease
(NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of …

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain
without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) …

Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

Non-alcoholic fatty liver disease (NAFLD) affects approximately 1 in 4 people worldwide and
is a major burden to health care systems. A major concern in NAFLD research is lack of …

A rapidly increasing incidence of non-alcoholic fatty liver disease (NAFLD) is noted
worldwide due to the adoption of western-type lifestyles and eating habits. This makes the …

Emerging evidence suggests a key contribution to non-alcoholic fatty liver disease (NAFLD)
pathogenesis by Th17 cells. The pathogenic characteristics and mechanisms of hepatic …

Gut microbiota dysbiosis plays an important role in the progression of non-alcoholic fatty
liver disease (NAFLD), and no approved drugs are available for NAFLD treatment. In this …

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from
simple steatosis to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and/or hepatocellular …

Background Animal models of non-alcoholic steatohepatitis (NASH) are important tools in
preclinical research and drug discovery. Gubra-Amylin NASH (GAN) diet-induced obese …